Lissa R. Herron

Lissa R. Herron

Auto-generated profile, based on publicly available information

Lissa R. Herron

The Roslin Institute, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, UK.

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2011 in Oncogene
Verified
Journal Article
Closed access
PDF file
LAL Angus
L Angus
SMS Moleirinho
S Moleirinho
LHL Herron
L Herron
ASA Sinha
A Sinha
XZX Zhang
X Zhang
FGFrank J. Gunn-Moore
Frank J. Gunn-Moore


1 January 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JGJames D. Garrity
James D. Garrity
ACAnne L. Carenbauer
Anne L. Carenbauer
LHLissa R. Herron
Lissa R. Herron
MCMichael W. Crowder
Michael W. Crowder
Metallo-β-lactamase L1 from Stenotrophomonas maltophilia is a dinuclear Zn(II) enzyme that contains a metal-binding aspartic acid in a position to potentially play an important role in catalysis. The presence of this metal-binding aspartic acid appears to be common to most dinuclear, metal-containing, hydrolytic enzymes; particularly those with a β-lactamase fold. In an effort to probe the catalytic and metal-binding role of Asp-120 in L1, three site-directed mutants (D120C, D120N, and D120S) were prepared and characterized using metal analyses, circular dichroism spectroscopy, and presteady-state and steady-state kinetics. The D120C, D120N, and D120S mutants were shown to bind 1.6 ± 0.2, 1.8 ± 0.2, and 1.1 ± 0.2 mol of Zn(II) per monomer, respectively. The mutants exhibited 10- to 1000-fold drops in kcat values as compared with wild-type L1, and a general trend of activity, wild-type > D120N > D120C and D120S, was observed for all substrates tested. Solvent isotope and pH dependence studies indicate one or more protons in flight, with pKa values outside the range of pH 5–10 (except D120N), during a rate-limiting step for all the enzymes. These data demonstrate that Asp-120 is crucial for L1 to bind its full complement of Zn(II) and subsequently for proper substrate binding to the enzyme. This work also confirms that Asp-120 plays a significant role in catalysis, presumably via hydrogen bonding with water, assisting in formation of the bridging hydroxide/water, and a rate-limiting proton transfer in the hydrolysis reaction.

14 April 2009 in Biochemical Journal
Verified
Journal Article
Open access
PDF file
LHLissa R. Herron
Lissa R. Herron
MHMaria Hill
Maria Hill
FDFleur Davey
Fleur Davey
FGFrank J. Gunn-Moore
Frank J. Gunn-Moore
The L1 family of CAMs (cell adhesion molecules) has long aroused the interest of researchers, but primarily the extracellular interactions of these proteins have been elucidated. More recently, attention has turned to the intracellular signalling potentiated by transmembrane proteins and the cytoplasmic proteins with which they can interact. The present review brings up to date the current body of published knowledge for the intracellular interactions of L1-CAM family proteins and the potential importance of these interactions for the mechanisms of L1-CAM action.

29 December 2018 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
LHLissa R. Herron
Lissa R. Herron
CPClare Pridans
Clare Pridans
MTMatthew L. Turnbull
Matthew L. Turnbull
NSNikki Smith
Nikki Smith
SLSimon Lillico
Simon Lillico
HSHelen M. Sang
Helen M. Sang
The global market for protein drugs has the highest compound annual growth rate of any pharmaceutical class but their availability, especially outside of the US market, is compromised by the high cost of manufacture and validation compared to traditional chemical drugs. Improvements in transgenic technologies allow valuable proteins to be produced by genetically-modified animals; several therapeutic proteins from such animal bioreactors are already on the market after successful clinical trials and regulatory approval. Chickens have lagged behind mammals in bioreactor development, despite a number of potential advantages, due to the historic difficulty in producing transgenic birds, but the production of therapeutic proteins in egg white of transgenic chickens would substantially lower costs across the entire production cycle compared to traditional cell culture-based production systems. This could lead to more affordable treatments and wider markets, including in developing countries and for animal health applications. Here we report the efficient generation of new transgenic chicken lines to optimize protein production in eggs. As proof-of-concept, we describe the expression, purification and functional characterization of three pharmaceutical proteins, the human cytokine interferon α2a and two species-specific Fc fusions of the cytokine CSF1. Our work optimizes and validates a transgenic chicken system for the cost-effective production of pure, high quality, biologically active protein for therapeutics and other applications.

25 August 2005 in FEBS Letters
Verified
Journal Article
Closed access
FGFrank J. Gunn-Moore
Frank J. Gunn-Moore
GWGavin Welsh
Gavin Welsh
LHLissa R. Herron
Lissa R. Herron
FBFrances Brannigan
Frances Brannigan
VKVenkateswarlu Kanamarlapudi
Venkateswarlu Kanamarlapudi
SGSimon Guild
Simon Guild